<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018105</url>
  </required_header>
  <id_info>
    <org_study_id>2018_35</org_study_id>
    <secondary_id>2019-001175-36</secondary_id>
    <nct_id>NCT04018105</nct_id>
  </id_info>
  <brief_title>Influence of Preprandial Metformin Administration on Carbohydrate Absorption</brief_title>
  <acronym>METTIME</acronym>
  <official_title>Influence of Preprandial Metformin Administration on Carbohydrate Absorption: Pilot Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes is spreading worldwide as well as obesity. Metformin is the most prescribed
      antidiabetic medication. One suggested mechanism of action is by decreasing carbohydrate
      absorption.

      It is usually recommended to take metformin during the meal to decrease gastrointestinal side
      effects. However, if metformin decreases carbohydrate absorption, this might not be the most
      efficient intake.

      To study the influence of preprandial metformin administration on carbohydrate absorption, it
      will repeat 3 oral glucose tolerance test on obese dysglycemic patients, without metformin or
      with metformin administer 30 or 60 minutes before. We will also evaluate how it impacts
      gastrointestinal tolerance.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve of D-Xylose</measure>
    <time_frame>During the 3 hours OGTT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with gastrointestinal side effects</measure>
    <time_frame>During the 3 hours OGTT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of blood glucose</measure>
    <time_frame>During the 3 hours OGTT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of insulin</measure>
    <time_frame>During the 3 hours OGTT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of GLP-1</measure>
    <time_frame>During the 3 hours OGTT</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>taking metformin 30 or 60 minutes before the OGTT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No metformin before OGTT</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral glucose tolerance test (OGTT) with or without metformin</intervention_name>
    <description>Each participant will have 3 OGTT, one without metformin, one with metformin30 minutes before the test, one with metformin 60 minutes before the test. The order for each test will be randomized.</description>
    <arm_group_label>No metformin before OGTT</arm_group_label>
    <arm_group_label>taking metformin 30 or 60 minutes before the OGTT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obesity (BMI ≥30 kg/m2)

          -  Dysglycemia (HbA1c≥ 6,0 %)

          -  No anti diabetic medication

        Exclusion Criteria:

          -  No obesity (BMI &lt; 30 kg/m2)

          -  No dysglycemia (HbA1c &lt;6,0%)

          -  Treatment that might interfere with carbohydrate absorption (anti diabetic medication,
             antibiotics, probiotics, steroids)

          -  Anemia (Hb &lt;12 g/dL)

          -  Organ failure

          -  Inflammatory Bowel Disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>camille Marciniak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Camille Marciniak, MD</last_name>
    <phone>03.20.44.67.37</phone>
    <phone_ext>+33</phone_ext>
    <email>camille.marciniak@chru-lille.fr</email>
  </overall_contact>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Impaired glucose tolerance</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>obesity</keyword>
  <keyword>carbohydrate absorption</keyword>
  <keyword>metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

